Clinical trial
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
NCT05368051 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
- Lead sponsor
- Beijing Friendship Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- October 1, 2021
- Completion date
- October 31, 2022
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.